Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 5 · newest first

  1. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimensAmerican Journal of Hematology · 2022
  2. A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaCancer · 2022
  3. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignanciesCancer · 2022
  4. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needBlood · 2022
  5. TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entityCancer · 2022
  6. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II TrialBlood · 2022
  7. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid LeukemiaBlood · 2022
  8. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLBlood Advances · 2022
  9. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemiaBlood Cancer Journal · 2022
  10. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLBlood Advances · 2022
  11. TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future DirectionsCancer Discovery · 2022
  12. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesAmerican Journal of Hematology · 2022
  13. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaAmerican Journal of Hematology · 2022
  14. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐AAmerican Journal of Hematology · 2022
  15. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsAmerican Journal of Hematology · 2022
  16. Contemporary outcomes in IDH ‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatmentAmerican Journal of Hematology · 2022
  17. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeBlood Advances · 2022
  18. Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysisAmerican Journal of Hematology · 2022
  19. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemiaAmerican Journal of Hematology · 2022
  20. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSNEJM Evidence · 2022
  21. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significanceLeukemia · 2022
  22. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysisBlood · 2022
  23. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directionsAmerican Journal of Hematology · 2022
  24. Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free RegimensJAMA Oncology · 2022
  25. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmJournal of Clinical Oncology · 2022
  26. Impact of SF3B1 mutation in myelofibrosisLeukemia & lymphoma/Leukemia and lymphoma · 2022
  27. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology · 2022
  28. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia · 2022
  29. Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higherAmerican Journal of Hematology · 2022
  30. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology · 2022
  31. Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higher-risk myelodysplastic syndrome (MDS).Journal of Clinical Oncology · 2022
  32. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.Journal of Clinical Oncology · 2022
  33. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.Journal of Clinical Oncology · 2022
  34. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemiaAmerican Journal of Hematology · 2022
  35. Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology · 2022
  36. TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysisAmerican Journal of Hematology · 2022
  37. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasmsBlood · 2022
  38. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AMLBlood Cancer Journal · 2022
  39. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cellsNature Communications · 2022
  40. Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE TrialClinical Lymphoma Myeloma & Leukemia · 2022
  41. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort studyCancer · 2022
  42. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsAmerican Journal of Hematology · 2022
  43. Prediction of survival with intensive chemotherapy in acute myeloid leukemiaAmerican Journal of Hematology · 2022
  44. Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsAmerican Journal of Hematology · 2022
  45. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomabAmerican Journal of Hematology · 2022
  46. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitorsLeukemia & lymphoma/Leukemia and lymphoma · 2022
  47. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALLLeukemia · 2022
  48. Time to blur the blast boundariesCancer · 2022
  49. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureJournal of Hematology & Oncology · 2022
  50. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapyBlood Cancer Journal · 2022